Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 08-09-2022 | Obesity | Review Article

¹²³I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation

Authors: Paola Gargiulo, Wanda Acampa, Gaetano Asile, Vincenza Abbate, Ermanno Nardi, Federica Marzano, Roberta Assante, Carmela Nappi, Antonio Luca Maria Parlati, Christian Basile, Santo Dellegrottaglie, Stefania Paolillo, Alberto Cuocolo, Pasquale Perrone-Filardi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2023

Abstract

Purpose

Heart failure (HF) is a primary cause of morbidity and mortality worldwide, with significant impact on life quality and extensive healthcare costs. Assessment of myocardial sympathetic innervation function plays a central role in prognosis assessment in HF patients. The aim of this review is to summarize the most recent evidence regarding the clinical applications of iodine-123 metaiodobenzylguanidine (¹²³I-MIBG) imaging in patients with HF and related comorbidities.

Methods

A comprehensive literature search was conducted on PubMed and Web of Science databases. Articles describing the impact of ¹²³I-MIBG imaging on HF and related comorbidities were considered eligible for the review.

Results

We collected several data reporting that ¹²³I-MIBG imaging is a safe and non-invasive tool to evaluate dysfunction of cardiac sympathetic neuronal function and to assess risk stratification in HF patients. HF is frequently associated with comorbidities that may affect cardiac adrenergic innervation. Furthermore, HF is frequently associated with comorbidities and chronic conditions, such as diabetes, obesity, kidney disease and others, that may affect cardiac adrenergic innervation.

Conclusion

Comorbidities and chronic conditions lead to more severe impairment of sympathetic nervous system in patients with HF, with a negative impact on disease progression and outcome. Cardiac imaging with ¹²³I-MIBG can be a useful tool to reduce morbidity and prevent adverse events in HF patients.

Available only for authorised users

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368.CrossRef

Currie GM, Iqbal B, Wheat JM, et al. Risk stratification in heart failure using 123I-MIBG. J Nucl Med Technol. 2011;39(4):295–301. https://doi.org/10.2967/jnmt.111.088369.CrossRef

Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30–8. https://doi.org/10.1038/nrcardio.2016.163.CrossRef

Carrió I, Cowie MR, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging. 2010;3(1):92–100. https://doi.org/10.1016/j.jcmg.2009.07.014.CrossRef

Pontico M, Brunotti G, Conte M, et al. The prognostic value of ¹²³I-mIBG SPECT cardiac imaging in heart failure patients: a systematic review. J Nucl Cardiol. 2022;29(4):1799–809. https://doi.org/10.1007/s12350-020-02501-w.CrossRef

Nappi C, Assante R, Zampella E, et al. Relationship between heart rate response and cardiac innervation in patients with suspected or known coronary artery disease. J Nucl Cardiol. 2021;28:2676–83. https://doi.org/10.1007/s12350-020-02091-7.CrossRef

Perrone-Filardi P, Paolillo S, Dellegrottaglie S, et al. Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. Heart. 2011;97(22):1828–33. https://doi.org/10.1136/heartjnl-2011-300343.CrossRef

Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212–21. https://doi.org/10.1016/j.jacc.2010.01.014.CrossRef

Rushton CA, Satchithananda DK, Jones PW, Kadam UT. Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: a systematic review and meta-analysis. Int J Cardiol. 2015;196:98–106. https://doi.org/10.1016/j.ijcard.2015.05.180.CrossRef

10.

Seo M, Yamada T, Tamaki S, et al. Prognostic significance of cardiac 123I-MIBG SPECT imaging in heart failure patients with preserved ejection fraction. JACC Cardiovasc Imaging. 2022;15:655–68. https://doi.org/10.1016/j.jcmg.2021.08.003.CrossRef

11.

Tamaki S, Yamada T, Watanabe T, et al. Usefulness of the 2-year iodine-123 metaiodobenzylguanidine-based risk model for post-discharge risk stratification of patients with acute decompensated heart failure. Eur J Nucl Med Mol Imaging. 2022;49:1906–17. https://doi.org/10.1007/s00259-021-05663-y.CrossRef

12.

Freeman AM, Pennings N. Insulin resistance. In: StatPearls. Treasure Island: StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK507839/.

13.

Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87(6):2246–52. https://doi.org/10.1172/JCI115260.CrossRef

14.

Watanabe K, Sekiya M, Tsuruoka T, et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens. 1999;17(8):1161–8. https://doi.org/10.1097/00004872-199917080-00016.CrossRef

15.

Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. https://doi.org/10.1016/0002-9149(74)90089-7.CrossRef

16.

Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853–72. https://doi.org/10.1002/ejhf.1170.CrossRef

17.

Rafanelli M, Walsh K, Hamdan MH, Buyan-Dent L. Autonomic dysfunction: diagnosis and management. Handb Clin Neurol. 2019;167:123–37. https://doi.org/10.1016/B978-0-12-804766-8.00008-X.CrossRef

18.

MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J. 2008;29(10):1224–40. https://doi.org/10.1093/eurheartj/ehn156.CrossRef

19.

Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow RO. The role of metabolic syndrome in heart failure. Eur Heart J. 2015;36(39):2630–4. https://doi.org/10.1093/eurheartj/ehv350.CrossRef

20.

Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 1995;25(3):610–8. https://doi.org/10.1016/0735-1097(94)00459-4.CrossRef

21.

Gerson MC, Caldwell JH, Ananthasubramaniam K, et al. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging. 2011;4(2):87–93. https://doi.org/10.1161/CIRCIMAGING.110.954784.CrossRef

22.

Paolillo S, Rengo G, Pagano G, et al. Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care. 2013;36(8):2395–401. https://doi.org/10.2337/dc12-2147.CrossRef

23.

Paolillo S, Rengo G, Pellegrino T, et al. Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. Eur Heart J Cardiovasc Imaging. 2015;16(10):1148–53. https://doi.org/10.1093/ehjci/jev061.CrossRef

24.

Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011–2016. JAMA. 2020;323(24):2526–8. https://doi.org/10.1001/jama.2020.4501.CrossRef

25.

Wang J, Sarnola K, Ruotsalainen S, et al. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis. 2010;210(1):237–42. https://doi.org/10.1016/j.atherosclerosis.2009.10.042.CrossRef

26.

Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. https://doi.org/10.1161/CIRCULATIONAHA.105.169404.CrossRef

27.

Canale MP, Manca di Villahermosa S, Martino G, et al. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol. 2013. https://doi.org/10.1155/2013/865965.

28.

Pellegrino T, Piscopo V, Boemio A, et al. Impact of obesity and acquisition protocol on (123)I-metaiodobenzylguanidine indexes of cardiac sympathetic innervation. Quant Imaging Med Surg. 2015;5(6):822–8. https://doi.org/10.3978/j.issn.2223-4292.2015.11.03.CrossRef

29.

Komici K, Bencivenga L, Paolillo S, et al. Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a (123)I-mIBG imaging study. Eur J Nucl Med Mol Imaging. 2020;47(7):1713–21. https://doi.org/10.1007/s00259-019-04658-0.CrossRef

30.

Parisi V, Rengo G, Perrone-Filardi P, et al. Increased epicardial adipose tissue volume correlates with cardiac sympathetic denervation in patients with heart failure. Circ Res. 2016;118(8):1244–53. https://doi.org/10.1161/CIRCRESAHA.115.307765.CrossRef

31.

Sunaga A, Hikoso S, Yamada T, et al. Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction. Eur J Nucl Med Mol Imaging. 2022;49(2):609–18. https://doi.org/10.1007/s00259-021-05280-9.CrossRef

32.

Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31(6):703–11. https://doi.org/10.1093/eurheartj/ehp507.CrossRef

33.

Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic kidney disease and cardiovascular disease: is there any relationship? Curr Cardiol Rev. 2019;15(1):55–63. https://doi.org/10.2174/1573403X14666180711124825.CrossRef

34.

Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113(5):671–8. https://doi.org/10.1161/CIRCULATIONAHA.105.580506.CrossRef

35.

Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: “Guyton revisited.” Eur Heart J. 2005;26(1):11–7. https://doi.org/10.1093/eurheartj/ehi020.CrossRef

36.

Doi T, Nakata T, Hashimoto A, et al. Cardiac mortality assessment improved by evaluation of cardiac sympathetic nerve activity in combination with hemoglobin and kidney function in chronic heart failure patients. J Nucl Med. 2012;53(5):731–40. https://doi.org/10.2967/jnumed.111.095786.CrossRef

37.

Verschure DO, Somsen GA, van Eck-Smit BLF, Verberne HJ. Renal function in relation to cardiac (123)I-MIBG scintigraphy in patients with chronic heart failure. Int J Mol Imaging. 2012;2012:434790. https://doi.org/10.1155/2012/434790.CrossRef

38.

Malhotra S, Wang L, Bunker CH, Winger D, Soman P. Renal dysfunction does not affect the prognostic value of myocardial iodine-123 meta-iodobenzylguanidine imaging in heart failure. Nucl Med Commun. 2014;35(1):58–63. https://doi.org/10.1097/MNM.0000000000000017.CrossRef

39.

Marsico F, Paolillo S, Gargiulo P, et al. Renal function and cardiac adrenergic impairment in patients affected by heart failure. J Nucl Cardiol. 2021;28(5):2112–22. https://doi.org/10.1007/s12350-019-01975-7.CrossRef

40.

Amami K, Yamada S, Yoshihisa A, et al. Predictive impacts of chronic kidney disease and cardiac sympathetic nervous activity on lethal arrhythmic events in chronic heart failure. Ann Noninvasive Electrocardiol. 2022;27:e12900. https://doi.org/10.1111/anec.12900.CrossRef

41.

de Lucia C, Piedepalumbo M, Paolisso G, Koch WJ. Sympathetic nervous system in age-related cardiovascular dysfunction: pathophysiology and therapeutic perspective. Int J Biochem Cell Biol. 2019;108:29–33. https://doi.org/10.1016/j.biocel.2019.01.004.CrossRef

42.

Ferrara N, Komici K, Corbi G, et al. β-adrenergic receptor responsiveness in aging heart and clinical implications. Front Physiol. 2014;4:396. https://doi.org/10.3389/fphys.2013.00396.CrossRef

43.

Estorch M, Carrió I, Berná L, López-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol. 1995;2(2 Pt 1):126–32. https://doi.org/10.1016/s1071-3581(95)80023-9.CrossRef

44.

Tsuchimochi S, Tamaki N, Tadamura E, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36(6):969–74.

45.

Jacobson AF, Chen J, Verdes L, Folks RD, Manatunga DN, Garcia EV. Impact of age on myocardial uptake of 123I-mIBG in older adult subjects without coronary heart disease. J Nucl Cardiol. 2013;20(3):406–14. https://doi.org/10.1007/s12350-013-9701-7.CrossRef

46.

Rengo G, Pagano G, Vitale DF, et al. Impact of aging on cardiac sympathetic innervation measured by (123)I-mIBG imaging in patients with systolic heart failure. Eur J Nucl Med Mol Imaging. 2016;43(13):2392–400. https://doi.org/10.1007/s00259-016-3432-3.CrossRef

47.

Javaheri S, Caref EB, Chen E, Tong KB, Abraham WT. Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med. 2011;183(4):539–46. https://doi.org/10.1164/rccm.201003-0406OC.CrossRef

48.

Mansukhani MP, Kara T, Caples SM, Somers VK. Chemoreflexes, sleep apnea, and sympathetic dysregulation. Curr Hypertens Rep. 2014;16(9):476. https://doi.org/10.1007/s11906-014-0476-2.CrossRef

49.

Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation. 2003;107(13):1822–6. https://doi.org/10.1161/01.CIR.0000061758.05044.64.CrossRef

50.

Hall AB, Ziadi MC, Leech JA, et al. Effects of short-term continuous positive airway pressure on myocardial sympathetic nerve function and energetics in patients with heart failure and obstructive sleep apnea: a randomized study. Circulation. 2014;130(11):892–901. https://doi.org/10.1161/CIRCULATIONAHA.113.005893.CrossRef

51.

Scala O, Paolillo S, Formisano R, et al. Sleep-disordered breathing, impaired cardiac adrenergic innervation and prognosis in heart failure. Heart. 2016;102(22):1813–9. https://doi.org/10.1136/heartjnl-2015-309215.CrossRef

52.

Tokuda Y, Sakakibara M, Yoshinaga K, et al. Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of (11)C-HED PET and (123)I-MIBG SPECT. J Nucl Cardiol. 2019;26:1079–89. https://doi.org/10.1007/s12350-017-1132-4.CrossRef

53.

Hayes MT. Parkinson’s disease and parkinsonism. Am J Med. 2019;132:802–7. https://doi.org/10.1016/j.amjmed.2019.03.001.CrossRef

54.

Gonçalves VC, Cuenca-Bermejo L, Fernandez-Villalba E, et al. Heart matters: cardiac dysfunction and other autonomic changes in Parkinson’s disease. Neuroscientist. 2021. https://doi.org/10.1177/1073858421990000.

55.

Kawazoe M, Arima H, Maeda T, et al. Sensitivity and specificity of cardiac (123)I-MIBG scintigraphy for diagnosis of early-phase Parkinson’s disease. J Neurol Sci. 2019;407:116409. https://doi.org/10.1016/j.jns.2019.07.027.CrossRef

56.

Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson’s disease: a review. Parkinsonism Relat Disord. 2014;20:267–73. https://doi.org/10.1016/j.parkreldis.2013.11.001.CrossRef

57.

Frantellizzi V, Ricci M, Farcomeni A, Pontico M, Pani A, Vincentis GD. Usefulness of 5 minutes ¹²³I-mIBG scan in Parkinson’s disease and heart failure. Curr Radiopharm. 2020;13:120–9. https://doi.org/10.2174/1874471013666200127122033.CrossRef

58.

Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease. Neurotherapeutics. 2020;17:1464–79. https://doi.org/10.1007/s13311-020-00897-4.CrossRef

59.

Oka H, Toyoda C, Yogo M, Mochio S. Cardiovascular dysautonomia in de novo Parkinson’s disease without orthostatic hypotension. Eur J Neurol. 2011;18:286–92. https://doi.org/10.1111/j.1468-1331.2010.03135.x.CrossRef

60.

Strano S, Fanciulli A, Rizzo M, et al. Cardiovascular dysfunction in untreated Parkinson’s disease: a multi-modality assessment. J Neurol Sci. 2016;370:251–5. https://doi.org/10.1016/j.jns.2016.09.036.CrossRef

61.

Steinberg BA, Al-Khatib SM, Edwards R, et al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail. 2014;2(6):623–9. https://doi.org/10.1016/j.jchf.2014.06.007.CrossRef

62.

Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51(3):288–96. https://doi.org/10.1016/j.jacc.2007.08.058.CrossRef

63.

Bencivenga L, Komici K, Femminella GD, et al. Impact of the number of comorbidities on cardiac sympathetic derangement in patients with reduced ejection fraction heart failure. Eur J Intern Med. 2021;86:86–90. https://doi.org/10.1016/j.ejim.2021.01.010.CrossRef

64.

Kayama K, Yamada T, Tamaki S, et al. Incremental prognostic value of cardiac metaiodobenzylguanidine imaging over the co-morbid burden in acute decompensated heart failure. ESC Heart Fail. 2021;8:1167–77. https://doi.org/10.1002/ehf2.13173.CrossRef

65.

Assante R, D’Antonio A, Mannarino T, et al. Simultaneous assessment of myocardial perfusion and adrenergic innervation in patients with heart failure by low-dose dual-isotope CZT SPECT imaging. J Nucl Cardiol. 2022. https://doi.org/10.1007/s12350-022-02951-4.

66.

van der Heijden AC, Borleffs CJW, Buiten MS, et al. The clinical course of patients with implantable cardioverter-defibrillators: extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm. 2015;12(6):1169–76. https://doi.org/10.1016/j.hrthm.2015.02.035.CrossRef

67.

Verschure DO, de Groot JR, Mirzaei S, et al. Cardiac (123)I-mIBG scintigraphy is associated with freedom of appropriate ICD therapy in stable chronic heart failure patients. Int J Cardiol. 2017;248:403–8. https://doi.org/10.1016/j.ijcard.2017.08.003.CrossRef

68.

Nakajima K, Nakata T, Doi T, Tada H, Maruyama K. Machine learning-based risk model using 123I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure. J Nucl Cardiol. 2022;29:190–201. https://doi.org/10.1007/s12350-020-02173-6.CrossRef

69.

Wan N, Travin MI. Cardiac imaging with (123)I-meta-iodobenzylguanidine and analogous PET tracers: current status and future perspectives. Semin Nucl Med. 2020;50:331–48. https://doi.org/10.1053/j.semnuclmed.2020.03.001.CrossRef

70.

Zelt JGE, deKemp RA, Rotstein BH, et al. Nuclear imaging of the cardiac sympathetic nervous system: a disease-specific interpretation in heart failure. JACC Cardiovasc Imaging. 2020;13:1036–54. https://doi.org/10.1016/j.jcmg.2019.01.042.CrossRef

Title: 123I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation
Authors: Paola Gargiulo
Wanda Acampa
Gaetano Asile
Vincenza Abbate
Ermanno Nardi
Federica Marzano
Roberta Assante
Carmela Nappi
Antonio Luca Maria Parlati
Christian Basile
Santo Dellegrottaglie
Stefania Paolillo
Alberto Cuocolo
Pasquale Perrone-Filardi
Publication date: 08-09-2022
Publisher: Springer Berlin Heidelberg
Keywords: Obesity
Obesity
Heart Failure
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05941-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹²³I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

The “complete diagnosis in one day” could be the next goal: the neuro-COVID paradigm

Metformin confers longitudinal cardiac protection by preserving mitochondrial homeostasis following myocardial ischemia/reperfusion injury

In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys

Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study

[18F]FAPI PET/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity

TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas